There were no significant news releases or other significant events that could be detected.
Heska engages in the discovery, development, manufacture, marketing, sale, distribution, and support of veterinary products primarily in the United States and Europe. The company operates in two segments, Core Companion Animal Health, and Other Vaccines Pharmaceuticals and Products.
The company is tiny, having a market cap of only $92 million. It has over $5 million in cash and more than $11 million in debt according to the latest Yahoo! financial data. Revenues and earnings have been increasing yearly over the last few years.
Company insiders have been buying shares on a regular basis over a two year span. Shares of Heska closed at $1.82 on Friday, just under the 52-week high of $1.90.
Heska has made BioWatch Alert List, and will be tracked for the next two weeks.
